<!-- Snapshot: live PubMed + real Claude extractor (--extractor llm) + real
     Claude reviewer (--reviewer claude), claude-opus-4-8. Live results evolve
     as the literature grows; every cited quote is verbatim in its source. -->

# Claim Audit Report

## Claim
> Vitamin D supplementation reduces the risk of cancer.

## Audit Verdict
**contradicted** (strength -0.60) — supports: 1×clinical; conflicts: 4×clinical; 7 indirect

## Evidence Map
- Independent sources: 1 supporting, 4 conflicting
- Sentences: 1 supporting · 7 conflicting · 7 indirect
- Records retrieved: 6

## Supporting Evidence
- [high | clinical | pubmed-38676447@1043-1208] Subsequent post hoc analyses have suggested, nevertheless, potential benefits in reducing cancer incidence, autoimmune diseases, cardiovascular events, and diabetes.

## Conflicting Evidence
- [high | clinical | pubmed-38676447@951-1042] The initial negative results are likely due to enrollment of vitamin D-replete individuals.
- [high | clinical | pubmed-30415629@985-1089] Supplementation with vitamin D was not associated with a lower risk of either of the primary end points.
- [high | clinical | pubmed-30415629@1090-1302] During a median follow-up of 5.3 years, cancer was diagnosed in 1617 participants (793 in the vitamin D group and 824 in the placebo group; hazard ratio, 0.96; 95% confidence interval [CI], 0.88 to 1.06; P=0.47).
- [high | clinical | pubmed-32405914@1244-1448] The effect estimate for vitamin D with or without calcium on breast cancer risk lay within the futility boundary, indicating that vitamin D supplementation does not alter the relative risk by 30% or more.
- [high | clinical | pubmed-32405914@1449-1577] Our analyses suggest that vitamin D supplementation, with or without calcium, does not reduce breast cancer risk by 30% or more.
- [high | clinical | pubmed-31733345@1088-1261] Updated meta-analyses that include VITAL and other recent vitamin D trials indicate a significant reduction in cancer mortality but not in cancer incidence or CVD endpoints.

## Indirect / Insufficient Evidence
- [high | clinical | pubmed-38676447@738-950] Beyond the well-known skeletal features, interest in vitamin D's extraskeletal effects has led to clinical trials on cancer, cardiovascular risk, respiratory effects, autoimmune diseases, diabetes, and mortality.
- [high | clinical | pubmed-30415629@1470-2058] In the analyses of secondary end points, the hazard ratios were as follows: for death from cancer (341 deaths), 0.83 (95% CI, 0.67 to 1.02); for breast cancer, 1.02 (95% CI, 0.79 to 1.31); for prostate cancer, 0.88 (95% CI, 0.72 to 1.07); for colorectal cancer, 1.09 (95% CI, 0.73 to 1.62); for the expanded composite end point of major cardiovascular events plus coronary revascularization, 0.96 (95% CI, 0.86 to 1.08); for myocardial infarction, 0.96 (95% CI, 0.78 to 1.19); for stroke, 0.95 (95% CI, 0.76 to 1.20); and for death from cardiovascular causes, 1.11 (95% CI, 0.88 to 1.40).
- [high | clinical | pubmed-32405914@117-304] However, the potential benefits of vitamin D supplementation to reduce the risk of breast cancer remain controversial, based on the results of current randomized controlled trials (RCTs).
- [high | clinical | pubmed-26510847@0-123] The aim was to meta-analyze randomized controlled trials of calcium plus vitamin D supplementation and fracture prevention.
- [medium | unspecified | pubmed-38935105@874-1203] Postmenopausal women with deficiencies of these nutrients are more vulnerable to comorbidities such as cardiovascular and cerebrovascular events, metabolic diseases, osteoporosis, obesity, cancer and neurodegenerative diseases such as Parkinson's disease, Alzheimer's disease, depression, cognitive decline, dementia, and stroke.
- [medium | unspecified | pubmed-38935105@1433-1790] In conclusion, maintaining optimum serum levels of nutrients and vitamins, either through a balanced and healthy diet consuming fresh fruits, vegetables, and fats or by taking appropriate supplementation, is essential in maintaining optimal health-related quality of life and reducing the risk for women during the menopausal transition and after menopause.
- [high | clinical | pubmed-31733345@1262-1397] Additional research is needed to determine which individuals may be most likely to derive a net benefit from vitamin D supplementation.

## Citation Audit
- 8/8 cited quotes are verbatim spans of their source (100% faithful).

## Overclaim Flags
- None.

## Contradiction Flags
- 🟡 Evidence conflicts: 1 supporting vs 4 conflicting independent source(s).

## Retrieval Gaps
- None.

## Reviewer Critique (claude)
_The verdict of 'contradicted' is well-supported for the claim as stated (reduces cancer *risk/incidence*). The largest RCT (VITAL) and a trial-sequential meta-analysis on breast cancer both show null effects on incidence. However, the card conflates two distinct endpoints: cancer *incidence* (consistently null) and cancer *mortality* (where evidence is more favorable). The claim should be split. The single 'supports' sentence is weak — it is a post hoc/narrative statement, not a primary trial result, and the same source notes initial negative results. Notably, pubmed-31733345's evidence sentence acknowledges a significant reduction in cancer mortality, which the card frames as 'conflicting' — this is a mischaracterization._
- **weak-citation:** The lone supporting sentence is a post hoc/narrative claim from a conference review, not a primary trial result, and the same source undercuts it. Should not be counted as independent clinical support. [pubmed-38676447: “Subsequent post hoc analyses have suggested, nevertheless, potential benefits in reducing cancer incidence, autoimmune diseases, cardiovascular events, and diabetes.”]
- **overclaim:** The card labels pubmed-31733345 as purely 'conflicting,' but its abstract reports a significant reduction in cancer mortality. Framing the whole source as conflicting overclaims the contradiction and hides a mortality benefit signal. [pubmed-31733345: “Updated meta-analyses that include VITAL and other recent vitamin D trials indicate a significant reduction in cancer mortality but not in cancer incidence or CVD endpoints.”]
- **missing-counter-evidence:** The card omits VITAL's cancer mortality signal, which counters a strict 'no benefit' reading. The claim needs to distinguish incidence (null) from mortality (possible benefit, especially with latency exclusion).
- **overclaim:** The breast cancer meta-analysis tested only a 30% relative risk reduction threshold (futility), not any effect. Citing it as evidence of no effect at all slightly overstates its scope. [pubmed-32405914: “indicating that vitamin D supplementation does not alter the relative risk by 30% or more”]
- **next-source:** Pull the D-Health Trial (Neale et al., Lancet Diabetes Endocrinol 2022, NCT01169259 is VITAL; D-Health is ACTRN12613000743763) — a large independent RCT of monthly vitamin D3 with cancer incidence and mortality endpoints — to test whether the VITAL mortality signal replicates and to add an independent clinical source beyond the VITAL-dominated evidence base.

## What Would Change My Mind?
- A well-powered result actually supporting the claim about the claim's entities, or a flaw in the conflicting studies — the evidence currently points against it.

## Suggested Next Checks
- Review cited records manually before drawing scientific conclusions.
- Add model-based claim extraction with citation-grounded outputs.
- Evaluate evidence support with a curated benchmark.

## Limitations
- Uses toy/sample abstracts by default; optional PubMed mode uses public metadata.
- Deterministic stance labeling is a scaffold for a future model-backed extractor.
- Evidence labels are illustrative research signals, not clinical guidance.
- Research signal only — not medical advice, not a validated clinical assessment.
